128 related articles for article (PubMed ID: 38651187)
1. PD-1 inhibition with retifanlimab and/or arginase inhibition with INCB001158 in Japanese patients with solid tumors: A phase I study.
Kuboki Y; Koyama T; Matsubara N; Naito Y; Kondo S; Harano K; Yonemori K; Yoh K; Gu Y; Mita T; Chen X; Ueda E; Yamamoto N; Doi T; Shimizu T
Cancer Med; 2024 Apr; 13(8):e6980. PubMed ID: 38651187
[TBL] [Abstract][Full Text] [Related]
2. A first-in-human phase I study of the PD-1 inhibitor, retifanlimab (INCMGA00012), in patients with advanced solid tumors (POD1UM-101).
Lakhani N; Cosman R; Banerji U; Rasco D; Tomaszewska-Kiecana M; Garralda E; Kornacki D; Li J; Tian C; Bourayou N; Powderly J
ESMO Open; 2024 Apr; 9(4):102254. PubMed ID: 38387109
[TBL] [Abstract][Full Text] [Related]
3. Dual CTLA-4 and PD-1 checkpoint blockade using CS1002 and CS1003 (nofazinlimab) in patients with advanced solid tumors: A first-in-human, dose-escalation, and dose-expansion study.
Bishnoi S; Kotasek D; Aghmesheh M; Yau T; Cosman R; Prawira A; Moore M; Chan SL; Mant A; Eek R; Zielinski R; Su R; Pan Z; Ma Y; Li F; Li P; Tse AN
Cancer; 2024 Jun; 130(11):1991-2002. PubMed ID: 38404184
[TBL] [Abstract][Full Text] [Related]
4. Phase IA/IB study of single-agent tislelizumab, an investigational anti-PD-1 antibody, in solid tumors.
Desai J; Deva S; Lee JS; Lin CC; Yen CJ; Chao Y; Keam B; Jameson M; Hou MM; Kang YK; Markman B; Lu CH; Rau KM; Lee KH; Horvath L; Friedlander M; Hill A; Sandhu S; Barlow P; Wu CY; Zhang Y; Liang L; Wu J; Paton V; Millward M
J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32540858
[TBL] [Abstract][Full Text] [Related]
5. A phase II study of retifanlimab (INCMGA00012) in patients with squamous carcinoma of the anal canal who have progressed following platinum-based chemotherapy (POD1UM-202).
Rao S; Anandappa G; Capdevila J; Dahan L; Evesque L; Kim S; Saunders MP; Gilbert DC; Jensen LH; Samalin E; Spindler KL; Tamberi S; Demols A; Guren MG; Arnold D; Fakih M; Kayyal T; Cornfeld M; Tian C; Catlett M; Smith M; Spano JP
ESMO Open; 2022 Aug; 7(4):100529. PubMed ID: 35816951
[TBL] [Abstract][Full Text] [Related]
6. Phase I study of the indoleamine 2,3-dioxygenase 1 inhibitor navoximod (GDC-0919) as monotherapy and in combination with the PD-L1 inhibitor atezolizumab in Japanese patients with advanced solid tumours.
Ebata T; Shimizu T; Fujiwara Y; Tamura K; Kondo S; Iwasa S; Yonemori K; Shimomura A; Kitano S; Koyama T; Sato N; Nakai K; Inatani M; Yamamoto N
Invest New Drugs; 2020 Apr; 38(2):468-477. PubMed ID: 31124055
[TBL] [Abstract][Full Text] [Related]
7. A phase II study of retifanlimab, a humanized anti-PD-1 monoclonal antibody, in patients with solid tumors (POD1UM-203).
Di Giacomo AM; Schenker M; Medioni J; Mandziuk S; Majem M; Gravis G; Cornfeld M; Ranganathan S; Lou S; Csoszi T
ESMO Open; 2024 Mar; 9(3):102387. PubMed ID: 38401247
[TBL] [Abstract][Full Text] [Related]
8. Pamiparib in combination with tislelizumab in patients with advanced solid tumours: results from the dose-escalation stage of a multicentre, open-label, phase 1a/b trial.
Friedlander M; Meniawy T; Markman B; Mileshkin L; Harnett P; Millward M; Lundy J; Freimund A; Norris C; Mu S; Wu J; Paton V; Gao B
Lancet Oncol; 2019 Sep; 20(9):1306-1315. PubMed ID: 31378459
[TBL] [Abstract][Full Text] [Related]
9. First-in-human phase I/Ib open-label dose-escalation study of GWN323 (anti-GITR) as a single agent and in combination with spartalizumab (anti-PD-1) in patients with advanced solid tumors and lymphomas.
Piha-Paul SA; Geva R; Tan TJ; Lim DW; Hierro C; Doi T; Rahma O; Lesokhin A; Luke JJ; Otero J; Nardi L; Singh A; Xyrafas A; Chen X; Mataraza J; Bedard PL
J Immunother Cancer; 2021 Aug; 9(8):. PubMed ID: 34389618
[TBL] [Abstract][Full Text] [Related]
10. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104
[TBL] [Abstract][Full Text] [Related]
11. Eganelisib, a First-in-Class PI3Kγ Inhibitor, in Patients with Advanced Solid Tumors: Results of the Phase 1/1b MARIO-1 Trial.
Hong DS; Postow M; Chmielowski B; Sullivan R; Patnaik A; Cohen EEW; Shapiro G; Steuer C; Gutierrez M; Yeckes-Rodin H; Ilaria R; O'Connell B; Peng J; Peng G; Zizlsperger N; Tolcher A; Wolchok JD
Clin Cancer Res; 2023 Jun; 29(12):2210-2219. PubMed ID: 37000164
[TBL] [Abstract][Full Text] [Related]
12. The safety and tolerability of epacadostat alone and in combination with pembrolizumab in patients with advanced solid tumors: results from a first-in-Japanese phase I study (KEYNOTE-434).
Doi T; Fujiwara Y; Shitara K; Shimizu T; Yonemori K; Matsubara N; Ohno I; Kogawa T; Naito Y; Leopold L; Munteanu M; Yatsuzuka N; Han SR; Samkari A; Yamamoto N
Invest New Drugs; 2021 Feb; 39(1):152-162. PubMed ID: 32564277
[TBL] [Abstract][Full Text] [Related]
13. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
Cochrane Database Syst Rev; 2021 Apr; 4(4):CD013257. PubMed ID: 33930176
[TBL] [Abstract][Full Text] [Related]
14. Axitinib in Combination With Toripalimab, a Humanized Immunoglobulin G
Sheng X; Yan X; Chi Z; Si L; Cui C; Tang B; Li S; Mao L; Lian B; Wang X; Bai X; Zhou L; Kong Y; Dai J; Wang K; Tang X; Zhou H; Wu H; Feng H; Yao S; Flaherty KT; Guo J
J Clin Oncol; 2019 Nov; 37(32):2987-2999. PubMed ID: 31403867
[TBL] [Abstract][Full Text] [Related]
15. Model Informed Dosing Regimen and Phase I Results of the Anti-PD-1 Antibody Budigalimab (ABBV-181).
Powderly J; Spira A; Kondo S; Doi T; Luke JJ; Rasco D; Gao B; Tanner M; Cassier PA; Gazzah A; Italiano A; Tosi D; Afar DE; Parikh A; Engelhardt B; Englert S; Lambert SL; Kasichayanula S; Mensing S; Menon R; Vosganian G; Tolcher A
Clin Transl Sci; 2021 Jan; 14(1):277-287. PubMed ID: 32770720
[TBL] [Abstract][Full Text] [Related]
16. Tislelizumab in Chinese patients with advanced solid tumors: an open-label, non-comparative, phase 1/2 study.
Shen L; Guo J; Zhang Q; Pan H; Yuan Y; Bai Y; Liu T; Zhou Q; Zhao J; Shu Y; Huang X; Wang S; Wang J; Zhou A; Ye D; Sun T; Gao Y; Yang S; Wang Z; Li J; Wu YL
J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32561638
[TBL] [Abstract][Full Text] [Related]
17. Margetuximab with retifanlimab as first-line therapy in HER2+/PD-L1+ unresectable or metastatic gastroesophageal adenocarcinoma: MAHOGANY cohort A.
Catenacci DVT; Kang YK; Yoon HH; Shim BY; Kim ST; Oh DY; Spira AI; Ulahannan SV; Avery EJ; Boland PM; Chao J; Chung HC; Gardner F; Klempner SJ; Lee KW; Oh SC; Peguero J; Sonbol MB; Shen L; Moehler M; Sun J; Li D; Rosales MK; Park H
ESMO Open; 2022 Oct; 7(5):100563. PubMed ID: 36029651
[TBL] [Abstract][Full Text] [Related]
18. A first-in-human phase 1 dose escalation study of spartalizumab (PDR001), an anti-PD-1 antibody, in patients with advanced solid tumors.
Naing A; Gainor JF; Gelderblom H; Forde PM; Butler MO; Lin CC; Sharma S; Ochoa de Olza M; Varga A; Taylor M; Schellens JHM; Wu H; Sun H; Silva AP; Faris J; Mataraza J; Cameron S; Bauer TM
J Immunother Cancer; 2020 Mar; 8(1):. PubMed ID: 32179633
[TBL] [Abstract][Full Text] [Related]
19. Safety, antitumor activity and biomarkers of sugemalimab in Chinese patients with advanced solid tumors or lymphomas: results from the first-in-human phase 1 trial.
Gong J; Cao J; Zhang Q; Xu N; Zhao Y; Xing B; Miao Z; Wu Y; Pan H; Gao Q; Li X; Liu B; Li W; Pei Z; Xia H; Qi Q; Dai H; Shi Q; Yang J; Li J; Shen L
Cancer Immunol Immunother; 2022 Aug; 71(8):1897-1908. PubMed ID: 34984540
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of camrelizumab combined with apatinib in advanced triple-negative breast cancer: an open-label phase II trial.
Liu J; Liu Q; Li Y; Li Q; Su F; Yao H; Su S; Wang Q; Jin L; Wang Y; Lau WY; Jiang Z; Song E
J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32448804
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
